Millipore Sigma Vibrant Logo

234409 Complement C9-Depleted Serum, Human

Complement C9-Depleted Serum, Human MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
View Products on Sigmaaldrich.com
234409
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
234409-1ML
Retrieving availability...
—
Fulfillment and delivery delayed Fulfillment and delivery delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 1 ml
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewHuman serum depleted of complement component C9 by affinity chromatography.
      Catalogue Number234409
      Brand Family Calbiochem®
      References
      Product Information
      Unit of Definition<b>Classical Pathway Activity:</b> One C9H50 unit measured by classical pathway activation is defined as the amount of C9 required to yield 50% lysis of 3 x 10⁷EA when incubated in the presence of the recommended volume of C9-Dpl for 30 min at 37°C in a total reaction volume of 500 µl GVB++. <b>CH50 Functional Activity upon Reconstitution:</b> One CH50 unit is defined as the input of C9-Dpl, reconstituted with C9, or NHS Complement Standard yielding 50% lysis of 1 x 10⁸ EA when incubated for 60 min at 37°C in a total reaction volume of 1.5 ml GVB++. <b>Alternative Pathway Activity:</b> One unit of whole alternative pathway activity (APH50) is defined as the input of C9-Dpl, reconstituted with C9, or NHS Complement Standard yielding 50% lysis of 1.5 x 10⁷ rabbit erythrocytes when incubated for 30 min at 37°C in a total reaction volume of 75 µl GVB° containing a final Mg-EGTA concentration of 13.3 mM.
      FormLiquid
      FormulationIn 150 mM NaCl, 50 mM sodium phosphate, pH 7.2 ± 0.2.
      PreservativeNone
      Applications
      Biological Information
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-I, and HIV-II.
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      234409-1ML 04055977200225

      Documentation

      Complement C9-Depleted Serum, Human SDS

      Title

      Safety Data Sheet (SDS) 

      Complement C9-Depleted Serum, Human Certificates of Analysis

      TitleLot Number
      234409

      Citations

      Title
    • Jose Yuste, et al. (2006) Roles of the Alternative Complement Pathway and C1q during Innate Immunity to Streptococcus pyogenes. Journal of Immunology 176, 6112-6120.
      		•
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-June-2008 RFH
      DescriptionHuman serum depleted of complement component C9 by affinity chromatography. C9-depleted serum, sterile-filtered through a 0.22 µm filter. No C9 detected by Ouchterlony using various dilutions of goat anti-human C9 antibody.
      FormLiquid
      FormulationIn 150 mM NaCl, 50 mM sodium phosphate, pH 7.2 ± 0.2.
      Concentration Label Please refer to vial label for lot-specific concentration
      Recommended reaction conditionsClassical Pathway Activity Recommended volume C9-Dpl serum per assay: ≤25 µl C9H50 units/mg purified C9 at the recommended input of C9-Dpl: ≥100,000 C9H50 units/mg Functional Activity Ratio: ≥0.60 (C9H50/mg C9 : C9H50/mg C9 in NHS Std.) CH50 Functional Activity upon Reconstitution Reconstitution Ratio: ≥0.60 (CH50/ml C9-Dpl + C9 : CH50/ml NHS Std) Alternative Pathway Activity Input of NHS Standard to yield 1 APH50: ≤20 µl
      SourcePrepared from serum that has been shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-I, and HIV-II.
      Unit definitionClassical Pathway Activity: One C9H50 unit measured by classical pathway activation is defined as the amount of C9 required to yield 50% lysis of 3 x 10⁷EA when incubated in the presence of the recommended volume of C9-Dpl for 30 min at 37°C in a total reaction volume of 500 µl GVB++. CH50 Functional Activity upon Reconstitution: One CH50 unit is defined as the input of C9-Dpl, reconstituted with C9, or NHS Complement Standard yielding 50% lysis of 1 x 10⁸ EA when incubated for 60 min at 37°C in a total reaction volume of 1.5 ml GVB++. Alternative Pathway Activity: One unit of whole alternative pathway activity (APH50) is defined as the input of C9-Dpl, reconstituted with C9, or NHS Complement Standard yielding 50% lysis of 1.5 x 10⁷ rabbit erythrocytes when incubated for 30 min at 37°C in a total reaction volume of 75 µl GVB° containing a final Mg-EGTA concentration of 13.3 mM.
      PreservativeNone
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      Citation
    • Jose Yuste, et al. (2006) Roles of the Alternative Complement Pathway and C1q during Innate Immunity to Streptococcus pyogenes. Journal of Immunology 176, 6112-6120.
      		•